{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Vatalanib",
  "nciThesaurus": {
    "casRegistry": "212141-54-3",
    "chebiId": "",
    "chemicalFormula": "C20H15ClN4",
    "definition": "An orally bioavailable anilinophthalazine with potential antineoplastic activity.  Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis.  This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.",
    "fdaUniiCode": "5DX9U76296",
    "identifier": "C1868",
    "preferredName": "Vatalanib",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C1742",
      "C1967"
    ],
    "synonyms": [
      "CGP 79787",
      "CGP-79787",
      "N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine",
      "PTK787",
      "PTK787/ZK 222584",
      "VATALANIB",
      "Vatalanib",
      "ZK-232934",
      "vatalanib"
    ]
  }
}